BURLINGTON, Mass., June 11, 2013 /PRNewswire/ -- inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services, announced today a strategic partnership with Medikly, Inc., an innovative provider of physician engagement solutions, as part of ongoing efforts to help pharmaceutical companies develop better drugs faster and more cost effectively – and get them to market more quickly.
Medikly's multichannel digital technology helps pharmaceutical companies identify, engage, and retain clinical trial investigators by applying a real-time view of doctors based on their preferences and behaviors online. Pharmaceutical companies gain a rich, multidimensional understanding of a physician's specific areas of interest, preferred method of communications, influence within their community, and a great deal more. Such insights help overcome barriers between those wanting to recruit investigators and the physician.
Medikly allows trial sponsors to discover physicians likely to be interested in becoming trial investigators because of their work and characteristics that predispose them to research or to recommend patients for a trial. The technology enables trial sponsors to create communities for investigators, develop relevant and sophisticated medical education programs, then measure and apply engagement metrics to understand how healthcare providers will respond to messages. It also allows a pharmaceutical company to expand trial awareness, build trust with physicians, accelerate acquisition rates, and improve relationships.
"By now, we all know that digital technologies can streamline clinical trials and save costs, but the challenge is knowing which technologies to use and how to best deploy them to save the most money and time," said Raymond Hill, President of Clinical for inVentiv Health. "This takes a special kind of expertise, grounded in broad global experience and deep insights into every aspect of drug development. inVentiv Health has that expertise and it is what drives our investment in technologies like Medikly to accelerate clinical trial success."
While Medikly is primarily focused on the marketing of pharmaceutical products, this agreement gives inVentiv Health exclusive access to their platform and data-collection tools to use in clinical trial recruitment.
"With the Medikly platform, inVentiv will be able to help pharmaceutical clients capture and translate multichannel data into insights and interactive experiences that reach and engage physicians," said Venkat Gullapalli, MD, CEO and Founder of Medikly. "inVentiv Health has had the foresight to leverage the right digital tools to position itself – and its customers – ahead of the curve."
Hill noted that inVentiv has 13,000 employees working collaboratively across the globe in diverse healthcare services, as well as a network of a half million healthcare providers, that together give the company the ability to forecast industry trends and opportunities. This allows the company to identify and integrate technologies that solve both current and future problems in ways that no one else can.
"Our approach to streamlining clinical trial recruitment of both physicians and patients is strategic, effective, cost efficient and fast," Hill said. "This is the future of clinical trial recruitment."
In May, the respected analyst firm Gartner Inc., identified Medlikly's platform as a "disruptive technology" and game-changing innovation for pharmaceutical organizations seeking "actionable insights" from detailed practitioner profiling across all available channels (social, face-to-face, mobile, digital, and web). The data facilitates personalized messaging and optimized sales efforts around the individual physician reduce wasted ... effort."
Earlier this year, inVentiv Health announced a strategic investment in Mytrus, which has launched the first FDA-approved electronic informed consent technology in the marketplace. Additional partnership announcements are planned for the coming weeks.
Medikly is pharma's first and only unified, cloud-based platform that helps brands, better reach, engage, and understand physicians on an individual level. Medikly's platform goes beyond current technology solutions by delivering deeper content, interactive experiences, while providing a robust set of measurable and actionable big data analytics. For more information, visit www.medikly.com or email email@example.com.
About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv's 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.
|SOURCE inVentiv Health, Inc.|
Copyright©2012 PR Newswire.
All rights reserved